^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    2d
    Romiplostim N01 in Combination Therapy for Initial Treatment of Severe Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Wuhan Union Hospital, China
    New P2 trial
    |
    Nplate (romiplostim)
    5d
    N01 ITP-002: Study on glucocorticoid combined with gamma globulin and Romiplostim N01 in treatment of initial severe ITP (ChiCTR2400088911)
    P=N/A, N=36, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New trial
    |
    Nplate (romiplostim)
    8d
    Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov)
    P3, N=240, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date
    10d
    Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery (clinicaltrials.gov)
    P2, N=60, Recruiting, Anhui Provincial Hospital
    New P2 trial • Surgery
    17d
    EPAG2015: Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, French Innovative Leukemia Organisation | Trial completion date: Sep 2024 --> Jul 2026
    Trial completion date
    |
    cytarabine • Promacta (eltrombopag)
    18d
    A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP (clinicaltrials.gov)
    P2, N=129, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    dexamethasone • Nplate (romiplostim)
    28d
    Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=63, Completed, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Rui Lisheng (romiplostim biosimilar)
    28d
    Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (clinicaltrials.gov)
    P3, N=162, Recruiting, Amgen | Trial completion date: Feb 2027 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Nplate (romiplostim)
    1m
    iROM2: Immunomodulation With Eltrombopag in ITP (clinicaltrials.gov)
    P2, N=2, Completed, University Children's Hospital Basel | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date • Immunomodulating
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    dexamethasone • Promacta (eltrombopag)
    1m
    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial
    |
    Promacta (eltrombopag)
    1m
    Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT (clinicaltrials.gov)
    P2/3, N=142, Recruiting, Peking University People's Hospital | Not yet recruiting --> Recruiting | Initiation date: Jan 2024 --> May 2024
    Enrollment open • Trial initiation date
    2ms
    Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Nplate (romiplostim)
    2ms
    Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclosporin A microemulsion
    2ms
    Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide
    2ms
    RESELECT2: REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Melbourne Health
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • Promacta (eltrombopag)
    2ms
    A single-center, randomized, controlled clinical study of Herombopag for the treatment of thrombocytopenia before liver resection (ChiCTR2400088598)
    P=N/A, N=96, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    2ms
    An open-label, single-arm study of Herombopag Olamine for the treatment of thrombocytopenia caused by PARPi (ChiCTR2400088126)
    P2, N=37, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    2ms
    An open-lable, single-arm pilot study to evaluate the efficacy and safety of lusutrombopag in Chinese adults with persistent or chronic immune thrombocytopenia (ChiCTR2400080388)
    P4, N=17, Recruiting, Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology&a | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    TPO-RA: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ianalumab (VAY736)
    2ms
    Extension Study of Hetrombopag in Severe Aplastic Anemia (clinicaltrials.gov)
    P3, N=157, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    3ms
    ELPOT: Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia (clinicaltrials.gov)
    P2, N=13, Completed, University Hospital, Toulouse | Recruiting --> Completed | N=25 --> 13
    Trial completion • Enrollment change • Surgery
    |
    Promacta (eltrombopag)
    3ms
    The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Sohag University
    New trial
    3ms
    Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia (clinicaltrials.gov)
    P4, N=55, Recruiting, The Third People's Hospital of Chengdu
    New P4 trial
    3ms
    The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov)
    P3, N=101, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    3ms
    Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Kyowa Kirin Co., Ltd. | Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2026
    Enrollment closed • Trial completion date
    |
    Nplate (romiplostim)
    3ms
    Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence (clinicaltrials.gov)
    P2, N=36, Recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2027 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag)
    4ms
    Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=43, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Jun 2027 --> Dec 2025 | Trial primary completion date: Jan 2027 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    4ms
    TPO-Mimetic Use in Children for Hematopoietic Failure (clinicaltrials.gov)
    P1, N=15, Completed, Anjali Sharathkumar | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2024
    Trial completion • Trial completion date
    |
    Nplate (romiplostim)
    4ms
    TE-ITP: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (clinicaltrials.gov)
    P4, N=157, Completed, Institute of Hematology & Blood Diseases Hospital, China | Active, not recruiting --> Completed
    Trial completion
    |
    Promacta (eltrombopag)
    4ms
    Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, Peking Union Medical College Hospital
    New P4 trial
    |
    Nplate (romiplostim)
    4ms
    Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=17, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Phase classification: P4 --> P2
    Phase classification
    4ms
    CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Promacta (eltrombopag)
    4ms
    Identification of Potential Inhibitors for Drug Resistance in Acute Lymphoblastic Leukemia through Differentially Expressed Gene Analysis and In Silico Screening. (PubMed, Anal Biochem)
    Our aim is to determine differentially expressed genes (DEGs) related to Asparaginase, Daunorubicin, Prednisolone, and Vincristine resistance and identify potential inhibitors via docking...Following ADMET analysis, three drugs emerged as potential inhibitors: Flunarizine, Talniflumate, and Eltrombopag...This study promotes a further understanding of drug resistance in ALL, introducing novel genes for consideration in diagnostic screening. It also presents potential inhibitor candidates to tackle drug resistance through repurposing.
    Journal
    |
    USP7 (Ubiquitin Specific Peptidase 7)
    |
    vincristine • daunorubicin • Promacta (eltrombopag)
    4ms
    The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov)
    P3, N=101, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial • Surgery
    4ms
    A single-arm, single-center, exploratory clinical study on the efficacy and safety of Herombopag Olamine Tabletsin in the treatment of breast cancer with thrombocytopenia caused by chemotherapy (ChiCTR2200062811)
    P2, N=82, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    4ms
    Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Geropharm
    New P3 trial
    |
    Nplate (romiplostim)
    4ms
    Outcomes in Bone Marrow Aplasia. (clinicaltrials.gov)
    P3, N=3, Not yet recruiting, Assiut University
    New P3 trial
    |
    Promacta (eltrombopag)
    4ms
    Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P4, N=17, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. (PubMed, Cell Prolif)
    BCAA deprivation alone did not effectively inhibit PCC proliferation. However, BCAA deprivation combined with eltrombopag, a drug targeting TFEB, can play a two-pronged role in exogenous supply deprivation and endogenous utilisation blockade to inhibit the proliferation of pancreatic cancer to the greatest extent, providing a new therapeutic direction, such as targeted metabolic reprogramming of pancreatic cancer.
    Journal
    |
    BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • TFEB (Transcription Factor EB 2)
    |
    Promacta (eltrombopag)
    5ms
    TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination (clinicaltrials.gov)
    P2, N=56, Recruiting, Peking Union Medical College Hospital
    New P2 trial
    |
    aspirin
    5ms
    TPO-Mimetic Use in Children for Hematopoietic Failure (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Anjali Sharathkumar | Trial primary completion date: Jun 2024 --> Jan 2024
    Trial primary completion date
    |
    Nplate (romiplostim)
    5ms
    CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2028 --> Mar 2029 | Trial primary completion date: Oct 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag)